IRIS
RIA, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.261
AS - Asia 5.882
EU - Europa 4.251
SA - Sud America 1.423
AF - Africa 256
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 2
Totale 26.088
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.039
SG - Singapore 2.506
CN - Cina 1.344
BR - Brasile 1.154
SE - Svezia 806
HK - Hong Kong 715
IT - Italia 670
RU - Federazione Russa 561
DE - Germania 544
VN - Vietnam 406
FR - Francia 352
FI - Finlandia 336
GB - Regno Unito 312
UA - Ucraina 274
IN - India 203
BD - Bangladesh 110
CA - Canada 103
AR - Argentina 94
ID - Indonesia 86
JP - Giappone 73
IQ - Iraq 70
MX - Messico 70
BE - Belgio 62
ZA - Sudafrica 60
CI - Costa d'Avorio 59
CO - Colombia 58
NL - Olanda 54
TR - Turchia 51
PK - Pakistan 50
IE - Irlanda 47
SA - Arabia Saudita 42
PL - Polonia 41
UZ - Uzbekistan 38
ES - Italia 37
PH - Filippine 37
VE - Venezuela 36
AT - Austria 33
CZ - Repubblica Ceca 31
MA - Marocco 29
LT - Lituania 27
EC - Ecuador 26
TN - Tunisia 20
EG - Egitto 19
AE - Emirati Arabi Uniti 18
JO - Giordania 18
KE - Kenya 18
MY - Malesia 17
PE - Perù 17
AU - Australia 11
CL - Cile 11
PY - Paraguay 10
UY - Uruguay 10
AL - Albania 9
IR - Iran 9
KR - Corea 9
RS - Serbia 9
AZ - Azerbaigian 8
NP - Nepal 8
DZ - Algeria 7
ET - Etiopia 7
IL - Israele 7
LB - Libano 7
OM - Oman 7
PA - Panama 7
JM - Giamaica 6
KW - Kuwait 6
PS - Palestinian Territory 6
PT - Portogallo 6
RO - Romania 6
TT - Trinidad e Tobago 6
CH - Svizzera 5
DO - Repubblica Dominicana 5
GR - Grecia 5
GT - Guatemala 5
MK - Macedonia 5
TH - Thailandia 5
BO - Bolivia 4
CR - Costa Rica 4
KZ - Kazakistan 4
SN - Senegal 4
SV - El Salvador 4
TW - Taiwan 4
AO - Angola 3
CG - Congo 3
HT - Haiti 3
HU - Ungheria 3
LY - Libia 3
NG - Nigeria 3
NO - Norvegia 3
QA - Qatar 3
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BH - Bahrain 2
CV - Capo Verde 2
CY - Cipro 2
EU - Europa 2
GE - Georgia 2
GH - Ghana 2
GM - Gambi 2
KG - Kirghizistan 2
Totale 26.043
Salva come PNG Salva come JPEG
Città #
Fairfield 1.541
Ashburn 1.538
Singapore 1.363
Chandler 1.140
Woodbridge 1.071
San Jose 878
Hong Kong 688
Houston 671
Seattle 641
Nyköping 596
Jacksonville 582
Cambridge 561
Wilmington 509
Ann Arbor 482
Beijing 405
New York 304
Los Angeles 225
Lauterbourg 213
Lawrence 213
Roxbury 212
Nanjing 204
Bari 175
Dallas 172
Helsinki 170
Des Moines 135
Munich 130
Ho Chi Minh City 120
Inglewood 111
Princeton 105
São Paulo 98
Boardman 93
Council Bluffs 91
Brooklyn 81
Buffalo 76
Santa Clara 69
Hanoi 68
London 67
San Diego 63
Brussels 60
Chicago 60
Abidjan 59
Falkenstein 58
Nanchang 57
Jakarta 52
Shenyang 52
Frankfurt am Main 50
Rome 49
Tokyo 49
Dublin 45
Moscow 44
Dearborn 42
Denver 40
Dong Ket 40
Montreal 39
Jiaxing 38
Orem 36
Baghdad 35
Tashkent 35
The Dalles 35
Stockholm 33
Columbus 32
Hebei 31
Pune 31
Chennai 30
Nuremberg 29
Toronto 29
Brno 28
Johannesburg 28
Marseille 28
Phoenix 28
Leawood 27
Tianjin 26
Paris 25
Washington 25
Belo Horizonte 24
Guangzhou 24
Mexico City 24
Amsterdam 23
Turku 23
Warsaw 23
San Francisco 22
Atlanta 21
Curitiba 21
Brasília 20
Changsha 20
Grafing 20
Haiphong 20
Milan 20
Poplar 20
Rio de Janeiro 20
Salt Lake City 20
Dhaka 19
Manchester 19
Salvador 19
Augusta 18
Jinan 18
Lahore 18
Amman 17
Boston 17
Osaka 17
Totale 17.793
Salva come PNG Salva come JPEG
Nome #
Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival 292
Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression 243
Central Function for JAM-a in Multiple Myeloma Patients with Extramedullary Disease. 216
Bone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients 209
Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets 190
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese" 188
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 187
Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma 185
Multiple myeloma macrophages: Pivotal players in the tumor microenvironment 183
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial 182
High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment 182
Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma–Enhanced Angiogenesis: A Novel Therapeutic Target? 180
Identify multiple myeloma stem cells: Utopia? 180
Evidence for bone marrow adult stem cell plasticity: Properties, molecular mechanisms, negative aspects, and clinical applications of hematopoietic and mesenchymal stem cells transdifferentiation 178
Functional and biological role of endothelial precursor cells in tumour progression: A new potential therapeutic target in haematological malignancies 176
Extramedullary Plasmacytoma Mimicking Pancreatic Cancer: An Unusual Presentation 175
Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies 173
Halting prosurvival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes Bortezomid resistance in multiple myeloma patients. 171
Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing 168
Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients 167
Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma 166
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 165
Neutropenia and G-CSF in lymphoproliferative diseases 162
Echocardiographic findings and plasma endothelin-1 levels in obese patients with and without obstructive sleep apnea 160
A multiple myeloma that progressed as type i cryoglobulinemia with skin ulcers and foot necrosis: A case report 159
Suspected Pericardial Tuberculosis Revealed as an Amyloid Pericardial Mass 155
Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients 154
Involvement of NOTCH signaling in multiple myeloma angiogenesis and progression 151
Serum Free Light Chains in Common Variable Immunodeficiency Disorders: Role in Differential Diagnosis and Association With Clinical Phenotype 151
A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target 151
Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: In vitro and in vivo studies 150
Bortezomib treatment modulates autophagy in multiple myeloma 148
90y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell trasplantation in aggressive non-Hodgkin lymphoma 147
Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials 145
Different Adaptive Responses to Hypoxia in Normal and Multiple Myeloma Endothelial Cells 143
Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma. 140
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: Clinical results and effects on microenvironment and neo-angiogenic biomarkers 140
A retrospective study of skeletal and disease-free survival benefits of zoledronic acid therapy in patients with multiple myeloma treated with novel agents 139
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20 139
Functional interplay between NIK and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma. 139
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials 139
Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma 136
Bortezomib Treatment Modulates Autophagy in Multiple Myeloma 136
Endothelial cells in the bone marrow of patients with multiple myeloma 135
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response 135
Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency Department 134
Is the efficacy of LDL apheresis in ischemic optic neuropathy linked to a reduction in endothelial activation markers? 133
Recurrent primary plasmacytoma of the eyelid with rapid regional metastasis 133
Inhibition of endothelial and plasma cells NOTCH mediated comunication reduces angiogenesis in multiple myeloma patients. 133
Metronomic chemotherapy from rationale to clinical studies: A dream or reality? 132
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis 131
Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma 131
Angiogenesis and Antiangiogenesis in Multiple Myeloma 131
Efficacy and safety of benralizumab in eosinophilic granulomatosis with polyangiitis: A meta‐analysis of eight studies 130
Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma 130
A weekly infusion of bortezomib reduces peripheral neuropathy 130
Imaging evaluation of pulmonary and non-ischaemic cardiovascular manifestations of covid-19 128
Bone marrow dendritic cells induce myeloma cell resistance to CD8+ T cell-mediated killing 127
High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin's lymphoma 127
Vascular Endothelial Growth Factor and its Receptors in Multiple Myeloma 126
High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma 126
Gene expression profiling of normal thyroid tissue from patients with thyroid carcinoma 125
Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts 124
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma 124
Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients 124
Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin’s lymphomas 124
An experimental study in the chick embryo chorioallantoic membrane of the anti-angiogenic activity of cyclosporine in rheumatoid arthritis versus osteoarthritis 124
Inhibition of Notch mediated communication in endothelial and plasma cells reduces angiogenesis in multiple myeloma patients. 123
Circulating miRNA markers show promise as new prognosticators for multiple myeloma 123
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial 122
Effect of thyroidectomy on circulating angiogenic cytokines in papillary thyroid carcinoma and benign goiter: Potential for new biomarkers? 122
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial 121
Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma 121
Could multiple myeloma VEGF modify the systemic microcirculation? 119
Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma 119
Fibrinogen apheresis in the treatment of peripheral arterial disease 118
Proteolytic activity of human lymphoid tumor cells. Correlation with tumor progression 118
Cardiovascular risk in patients with Takayasu arteritis directly correlates with diastolic dysfunction and inflammatory cell infiltration in the vessel wall: a clinical, ex vivo and in vitro analysis. 117
Circulating cell adhesion molecules are increased in hypertensive left ventricular hypertrophy 116
Delayed complete remission in a patient with multiple myeloma 116
Proangiogenic effect of bone marrow fibroblasts in patients with multiple myeloma 116
Angiogenesis in multiple myeloma 114
Effect of low-density lipoprotein apheresis on circulating endothelial progenitor cells in familial hypercholesterolemia 113
Does a reduction of adhesion molecules by LDL-apheresis have a role in the treatment of sudden hearing loss? 113
Efficacy of filgrastim, lenograstim and peg-filgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative disorders. 113
HIF-1a of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target 113
Novel agents and new therapeutic approaches for treatment of multiple myeloma 113
A VEGF-dependent autocrine loop on endothelial cells pomotes angiogenesis and progression in multiple myeloma 112
Efficacy and safety of once weekly bortezomib in multiple myeloma patients 109
Angiogenesi e progressione tumorale nel melanoma 108
TNP-470 and recombinant human interferon-alpha2a inhibit angiogenesis synergistically 107
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 107
In vivo time-course of the angiogenic response induced by multiple myeloma plasma cells in the chick embryo chorioallantoic membrane 107
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma 107
Mast cell contribution to angiogenesis related to tumour progression 105
Development of vasculature targeting strategies for the treatment of chronic inflammatory diseases 105
Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients 105
Right Heart Changes Impact on Clinical Phenotype of Amyloid Cardiac Involvement: A Single Centre Study 105
Cancer-related coagulopathy (Trousseau's syndrome): Review of the literature and experience of a single center of internal medicine 104
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma 104
Totale 14.072
Salva come PNG Salva come JPEG
Categoria #
all - tutte 109.303
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 109.303
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021762 0 0 0 0 0 0 0 0 0 335 254 173
2021/20221.640 153 203 17 52 63 106 92 84 95 122 272 381
2022/20232.877 379 299 184 280 329 421 21 304 528 22 53 57
2023/20241.179 100 196 71 60 104 328 60 71 7 22 30 130
2024/20254.481 127 96 322 204 122 412 421 432 186 272 694 1.193
2025/20268.254 1.384 401 526 973 1.081 592 1.053 310 1.128 806 0 0
Totale 26.794